CorePharm Bio wins patent dispute against ‘Astellas, a multinational pharma
CorePharm Bio(CEO Jung-Tae Kim) announced that the Patent Court ruled the company’s A-Care Tab(generic name: solifenacin fumarate) does not infringe the Astellas’ solifenacin substance patent on the 30th of June.
The Patent Court ruled “A patent whose term of existence is extended can be interpr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
